Management Change/Compensation Form 8 K

On September 23, 2024, (the "Grant Date"), the Compensation Committee (the "Compensation Committee") of the Board of Directors (the "Board") of Avenue Therapeutics, Inc. (the "Company") and the Board, respectively, approved the granting of equity awards under the Company's 2015 Incentive Plan, as amended (the "Plan"), to certain named executive officers as follows: (a) an award of 170,000 restricted stock units to Alexandra MacLean, M.D. ("MacLean"), the Company's Chief Executive Officer (the "MacLean RSUs"), and (b) an award of 65,000 restricted stock units to David Jin ("Jin"), the Company's Interim Principal Financial Officer and Chief Operating Officer (the "Jin RSUs" and together with the MacLean RSUs, the "RSUs"). The RSUs vest in four equal installments on each of the following dates: September 30, 2024, December 31, 2024, September 20, 2025, and September 20, 2026 (each an "RSU Vesting Date"), provided that the grantee provides continuous service to the Company from the Grant Date through the applicable RSU Vesting Date and subject to the other terms of the restricted stock unit agreement ("RSU Agreement"). Once vested, the settlement of the RSUs will be deferred until the earlier of the tenth business day of January of the year following termination of service of the recipient to the Company under certain conditions and/or the occurrence of a Change in Control event (as defined in the Plan).

The RSUs were granted pursuant to an RSU Agreement, the form of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 5.02.